Arrowhead pharmaceuticals announces closing of global license and collaboration agreement with sarepta therapeutics

Pasadena, calif.--(business wire)---- $arwr--arrowhead pharmaceuticals, inc. (nasdaq: arwr) today announced that the global licensing and collaboration agreement with sarepta therapeutics (nasdaq: srpt) announced on november 26, 2024, has now closed. closing of the transaction was subject to the expiration or termination of the waiting period under the hart-scott-rodino antitrust improvements act of 1976 and other customary conditions. summary financial terms upon closing, arrowhead receives a $500 milli.
SRPT Ratings Summary
SRPT Quant Ranking